1. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review;Falade-Nwulia;Ann Intern Med,2017
2. FDA Drug Safety Communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie,2015
3. United States Food and Drug Administration. FDA Drug Safety Communication: FDA warns about rare occurrence of serious liver injury with use of hepatitis C medicines Mavyret, Zepatier, and Vosevi in some patients with advanced liver disease. Accessed at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-occurrence-serious-liver-injury-use-hepatitis-c-medicines-mavyret-zepatier-and. [Accessed on March 28, 2021].
4. An update on the toxicological considerations for protease inhibitors used for hepatitis C infection;Mak;Expert Opin Drug Metab Toxicol,2018
5. American Association for the Study of Liver Diseases/Infectious Diseases Society of America. HCV Guidance: recommendations for testing m, and treating hepatitis C. Accessed at: https://www.hcvguidelines.org. [Accessed on March 28, 2021].